company background image
KSPH.F logo

Kissei Pharmaceutical OTCPK:KSPH.F Stock Report

Last Price

US$25.00

Market Cap

US$1.1b

7D

0%

1Y

n/a

Updated

04 Nov, 2024

Data

Company Financials +

Kissei Pharmaceutical Co., Ltd.

OTCPK:KSPH.F Stock Report

Market Cap: US$1.1b

Kissei Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kissei Pharmaceutical
Historical stock prices
Current Share PriceJP¥25.00
52 Week HighJP¥25.00
52 Week LowJP¥19.32
Beta0.017
11 Month Change0%
3 Month Change16.39%
1 Year Changen/a
33 Year Changen/a
5 Year Change-3.06%
Change since IPO24.07%

Recent News & Updates

Recent updates

Shareholder Returns

KSPH.FUS PharmaceuticalsUS Market
7D0%-3.7%-1.6%
1Yn/a17.2%30.8%

Return vs Industry: Insufficient data to determine how KSPH.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how KSPH.F performed against the US Market.

Price Volatility

Is KSPH.F's price volatile compared to industry and market?
KSPH.F volatility
KSPH.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: KSPH.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine KSPH.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19461,779Mutsuo Kanzawawww.kissei.co.jp

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients.

Kissei Pharmaceutical Co., Ltd. Fundamentals Summary

How do Kissei Pharmaceutical's earnings and revenue compare to its market cap?
KSPH.F fundamental statistics
Market capUS$1.09b
Earnings (TTM)US$79.19m
Revenue (TTM)US$510.90m

13.8x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KSPH.F income statement (TTM)
RevenueJP¥77.43b
Cost of RevenueJP¥38.79b
Gross ProfitJP¥38.64b
Other ExpensesJP¥26.64b
EarningsJP¥12.00b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 05, 2024

Earnings per share (EPS)271.48
Gross Margin49.90%
Net Profit Margin15.50%
Debt/Equity Ratio0.6%

How did KSPH.F perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

31%

Payout Ratio